Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 8Rhabdomyosarcoma 8Wilms Tumor 7Malignant mesenchymal tumor 5Kidney Neoplasms 4Rhabdomyosarcoma, Embryonal 3Neuroectodermal Tumors, Primitive, Peripheral 3Rhabdomyosarcoma, Alveolar 2Hydatidiform Mole 2Gestational Trophoblastic Disease 2Stage I Mixed Cell Type Kidney Wilms Tumor 1Sarcoma, Ewing 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Lymphoma 1Liposarcoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1Fibrosarcoma 1Desmoplastic Small Round Cell Tumor 1Choroid Plexus Neoplasms 1Choriocarcinoma 1Brain Neoplasms 1Blast Crisis 1Beckwith-Wiedemann Syndrome 1

Interventions

Vinorelbine 2Vincristine 2Radiotherapy 2Radiation 2Dactinomycin 2Cyclophosphamide 2temsirolimus 1dinutuximab 1X-Rays 1Specimen Handling 1Sirolimus 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Irinotecan 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Rhabdomyosarcoma, Alveolar × Dactinomycin × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT04994132 2026-05-05

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Children's Oncology Group

Phase 3 Active not recruiting
118 enrolled
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡